|Download document||Second draft guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation|
|Status||draft: consultation open|
|Consultation start date||15/11/2013|
|Consultation end date||15/01/2014|
|Email address for email@example.com|
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. AF confers a 5-fold risk of stroke, and one in five of all strokes is attributed to this arrhythmia.